Gilead HIV combo warning
Triple nucleoside reverse transcriptase inhibitor regimen containing Gilead's Viread (tenofovir), GlaxoSmithKline's Epivir (lamivudine) and Bristol-Myers Squibb's Videx (didanosine) "is not recommended when considering a new treatment regimen for therapy-naïve or experienced patients with HIV-infection," a Gilead "Dear Doctor" letter sent Oct. 14 says. The combination therapy was associated with a "high rate of early virologic failure and emergence of NRTI resistance associated mutations" in a clinical study. A recent GSK "Dear Doctor" letter warned against use of therapy combining GSK's Ziagen (abacavir), Viread and Epivir (1"The Pink Sheet" Aug. 4, 2003, In Brief)...
You may also be interested in...
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
India is allowing importers and manufacturers of certain devices – for whom new licensing requirements came into effect on 1 January – to continue marketing their products for six months if they have already applied for a license. See what Rajiv Nath from the Association of Indian Medical Device Industry (AiMeD) said about it here.